Clinical significance of antinuclear antibodies in primary immune thrombocytopenia

Guillaume Moulis; Nathalie Aladjidi; Bertrand Godeau

doi:10.1111/bjh.19069

Clinical significance of antinuclear antibodies in primary immune thrombocytopenia

Br J Haematol. 2023 Oct;203(1):131-135. doi: 10.1111/bjh.19069. Epub 2023 Aug 30.

Authors

Guillaume Moulis^{1

2}, Nathalie Aladjidi³, Bertrand Godeau⁴

Affiliations

¹ Department of Internal Medicine, Referral Center for Autoimmune Cytopenia in Adults, Toulouse University Hospital, Toulouse, France.
² Clinical Investigation Center 1436, Team PEPSS, Toulouse University Hospital, Toulouse, France.
³ Pediatric Hemato-Immunology, Referral Center for Autoimmune Cytopenia in Children, CEREVANCE, CIC1401, INSERM CICP, Bordeaux University Hospital, Bordeaux, France.
⁴ Internal Medicine Department, Referral Center for Autoimmune Cytopenia in Adults, Hospital Henri Mondor, University Hospital Federation TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique Hôpitaux de Paris (AP-HP), University of Paris Est Créteil, Créteil, France.

PMID: 37646171
DOI: 10.1111/bjh.19069

Abstract

There are discrepancies across guidelines about whether the dosage of antinuclear antibodies (ANAs) is of use at the diagnosis of primary immune thrombocytopenia (ITP). This review describes the current knowledge about ANA prevalence in patients with primary ITP, and their potential usefulness as biomarkers for ITP evolution, response to treatments and increased risk of subsequent development of systemic lupus and thrombosis.

Keywords: antinuclear antibodies; epidemiology; immune thrombocytopenia; lupus.

Publication types

Review

MeSH terms

Antibodies, Antinuclear*
Clinical Relevance
Humans
Purpura, Thrombocytopenic, Idiopathic* / diagnosis

Substances

Antibodies, Antinuclear